HPV vaccine trial aims to protect women with HIV from cervical cancer

NCT ID NCT06281119

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Serum Institute of India Pvt. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests Cervavac, an HPV vaccine, in women aged 15-25 who are living with HIV. HPV infection can lead to cervical cancer, and women with HIV are at higher risk. The trial compares two-dose and three-dose schedules of Cervavac against a standard vaccine to see how well they work and if they are safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cervavac (quadrivalent HPV vaccine)
What this could lead to: If successful, this could show that Cervavac is safe and effective for women with HIV, helping prevent cervical cancer in a high-risk group.
What could go wrong: This is a Phase 3b study, so results are not yet confirmed. The vaccine may not work as well in women with HIV, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMAVIRUS INFECTION

Contacts and locations

Locations

Centre For Clinical Research, Kemri

Nairobi, 54840-00200, Kenya
Clinical HIV Research Unit (CHRU), Helen Joseph Hospital

Johannesburg, 2092, South Africa
Manhiça Health Research Center - Manhiça Foundation (CISM-FM)

Manhiça, 1929, Mozambique
Partners in Health and Research Development (Phrd)

Thika, 19865-00202, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.